Contraceptive implant use among inner city teens.
OBJECTIVE
This study develops a clinical profile of urban teens who selected Norplant for contraception; determines which variables identify the subjects most likely to be compliant with the method; and determines the most common reasons for early termination of use.


METHODS
Demographic and health history data and reasons for termination of use were collected prospectively for 122 inner city teens who received Norplant. Life table analysis and the Mantel-Haenszel procedure were used to investigate differences between Norplant retainers and terminators.


RESULTS
The sample consisted of black and Hispanic teens between the ages of 13-19 years, the majority of whom had one or more children and were in school. One and two year retention rates were 71% and 62%. The highest removal rates occurred during the 3-6 month interval after insertion. A significant finding was that teens who have experienced induced abortion were more likely to retain Norplant. Common reasons for termination of use included general and social concerns, including pregnancy desire.


CONCLUSIONS
Norplant retention rates for this teen sample were greater than the compliance rates reported for other conventional methods. Similar to noncompliance with oral contraceptives, discontinuance of the method was most likely to occur in the first 6 months of use. A history of induced abortion identifies those teens most likely to retain Norplant, suggesting that these teens might evaluate contraceptive risks and benefits differently than those with no abortion history. Pregnancy desire was a common reason for terminating Norplant use.
Glantz
S
S
Anthony Jordan Health Center, Rochester, NY 14605, USA.
Schaff
E
E
Campbell-Heider
N
N
Glantz
J C
JC
Bartlett
M
M
D000293:Adolescent; D001741:Black or African American / Q000706:statistics & numerical data; D004343:Drug Implants; D005260:Female; D006630:Hispanic or Latino / Q000706:statistics & numerical data; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D009518:New York; D010349:Patient Compliance; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011203:Poverty / Q000706:statistics & numerical data; D011446:Prospective Studies; D012959:Socioeconomic Factors; D014505:Urban Population / Q000706:statistics & numerical data
D004343:Drug Implants; D016912:Levonorgestrel